Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | 0.00% | +5.96% | -39.12% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
Financials (USD)
Sales 2024 * | 455M | Sales 2025 * | 490M | Capitalization | 330M |
---|---|---|---|---|---|
Net income 2024 * | -2M | Net income 2025 * | 8M | EV / Sales 2024 * | 0.69 x |
Net cash position 2024 * | 15.31M | Net cash position 2025 * | 14.68M | EV / Sales 2025 * | 0.64 x |
P/E ratio 2024 * |
-187
x | P/E ratio 2025 * |
26.2
x | Employees | 862 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.36% |
Latest transcript on Organogenesis Holdings Inc.
1 week | +5.96% | ||
Current month | +5.96% | ||
1 month | -11.07% | ||
3 months | -25.23% | ||
6 months | +5.06% | ||
Current year | -39.12% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Gillheeney
CEO | Chief Executive Officer | 69 | 13-12-31 |
David Francisco
DFI | Director of Finance/CFO | 59 | 21-02-15 |
Patrick Bilbo
COO | Chief Operating Officer | 63 | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Nussdorf
BRD | Director/Board Member | 70 | 02-12-31 |
Alan Ades
BRD | Director/Board Member | 86 | 02-12-31 |
Michael Driscoll
BRD | Director/Board Member | 63 | 22-02-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 27 M€ | -4.14% | - | |
0.09% | 29 M€ | -2.99% | ||
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 2.49 | 0.00% | 895,051 |
24-05-02 | 2.49 | -0.80% | 3,006,636 |
24-05-01 | 2.51 | +6.81% | 462,786 |
24-04-30 | 2.35 | -4.28% | 263,990 |
24-04-29 | 2.455 | +4.47% | 1,037,126 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.12% | 330M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ORGO Stock